Targeting Rheumatoid Arthritis disease where it strikes — in the joints — in 70 million people worldwide

DeMay Bio’s goal is to develop an adjunct therapy for Rheumatoid Arthritis that directly targets the harmful cellular changes that cause joint pain, tissue damage and disabling mobility loss.  Our treatment is designed to work with a patient’s existing immune suppressive therapy — to better and more safely control disease signs, and to prevent and manage painful and debilitating flares.

%d bloggers like this: